Search

Your search keyword '"Van Kammen, D. P."' showing total 279 results
Start Over Author "Van Kammen, D. P."
279 results on '"Van Kammen, D. P."'

6. Third Annual Huntington Disease Clinical Research Symposium: Organized by the Huntington Study Group

Author

Dubinsky, Richard, Roberson, Judy, Battaglia, G., Cannella, M., Riozzi, B., Orobello, S., Maat-Schieman, M. L., Aronica, E., Busceti, C. Letizia, Ciarmiello, A., Alberti, S., Sassone, J., Sipione, S., Bruno, V., Frati, L., Nicoletti, F., Squitieri, F., Rao, A., Gordon, A., Marder, K., Nolta, Jan, Anderson, K., Gruber-Baldini, A., Medalie, J., Reich, S., Fishman, P., Robottom, B., Weiner, W., Shulman, L., Langbehn, D., Paulsen, J., Witten, Celia, Cox, M., Feigin, A., Napolitano, B., Goh, A., Yastrubetskaya, O., Chiu, E., Cloud, L., Helmers, S., Jones, R., Factor, S., Emory, C. Testa, Kegelmeyer, D., Kostyk, S., Fritz, N., Kloos, A., Lessig, S., Goldstein, J., Corey-Bloom, J., Simonelli, M., Martino, T., Colonnese, C., Callaghan, J., Arran, N., Boisse, M. F., Coleman, A., Dar Santos, R., Dumas, E., Hart, E. ’t, Justo, D., Read, J., Say, M., Van Den Bogaard, S., Durr, A., Leavitt, B., Roos, R., Tabrizi, S., Bourdet, C., van Duijn, E., Craufurd, D., Evans, K., Vaccarino, A., Aylward, E., Nopoulos, P., Ross, C., Pierson, R., Mills, J., Magnotta, V., Johnson, H., Mitchell, A., Cortes, J. C., Dahmubed, A., Krakauer, J., Mazzoni, P., Russell, D., Jennings, D., Tamagnan, G., Seibyl, J., Koren, A., Zubal, G., Marek, K., Goodman, L., Carnes, R., Giuliano, J., Vetter, L., MacDonald, M., Lee, J. Min, Seong, I. Sik, Fossale, E., Anderson, M. A., Wheeler, V., Gusella, J., Johnson, J., Yu, T., Jones, D., Chan, A., Richardson, K., McCusker, E., Loy, C., Griffith, J., Paulsen, J. S., Waters, S., Tedroff, J., Kieburtz, K., Krogh, P. Lindskov, Buusman, A., Rembratt, Å., Dorey, J., Lamure, M., Toumi, M., von der Schulenburg, J. -M. Graf, Pettersson, F., Dyhring, T., Sonesson, C., Waters, N., Pontén, H., Erwin, C., Williams, J., Juhl, A., Adams, W., Byars, J., O’Rourke, J., Flynn, A., Fiedorowicz, J., Duff, K., Leserman, A., Beglinger, L., Smith, M., Stout, J., Queller, S., Rao, S., Zimbelman, J., Groves, M., Guttman, M., Wexler, E., Perlman, S., Burgunder, J. -M., Rosenblatt, A., van Kammen, D., PREDICT-HD Investigators of the Huntington Study Group, TRACK-FID Investigators, TRACK-HD Investigators, PREDICT-HD Investigators and Coordinators of the Huntington Study Group, PREDICT-HD Investigators of the Huntington Study Group, Investigators of the Huntington Study Group, Huntington Study Group PHAROS Investigators, and PREDICT-HD Investigators of the Huntington Study Group

Published
2010
Full Text
View/download PDF

7. Second Annual Huntington Disease Clinical Research Symposium: Organized by the Huntington Study Group

Author

Sabine, Charles, Trembath, K., Churchyard, A., Horton, Z., Tippett, L., Hogg, V., Roxburgh, R., Velakoulis, D., Collins, V., Delatycki, M., Aylward, E., Nopoulos, P., Johnson, H., Juhl, A., Magnotta, V., Pierson, R., Langbehn, D., Ross, C., Paulsen, J., Maltby, Lewis, Poston, K. L., Tang, C., Feigin, A., Ma, Y., Guttman, M., Paulsen, J. S., Dhawan, V., Eidelberg, D., Katz, Russell, Goodman, L. Veatch, Giuliano, J., Lovecky, D., Quaid, K., Dure, L., Goh, A., Yastrubetskaya, O., Chiu, E., Evans, K., Anderson, K., Borowsky, B., Duff, K., Ho, A., Sills, T., Vaccarino, A., Van Kammen, D., Block, R. C., Dorsey, E. R., Beck, C. A., Shoulson, I., Pirogovsky, E., Bartlett, B., Callazo, A., Goldstein, J., Peavy, G., Jacobson, M., Corey-Bloom, J., Gilbert, P., Lessig, S., Peavy, G. M., Weaver, K. E., Richards, T. L., Liang, O., Aylward, E. H., Beglinger, L. J., Adams, W. H., Paulson, H., Fiedorowicz, J. G., Langbehn, D. R., Leserman, A., Conley, K. E., Jubrias, S., Amara, C., Shankland, E., Marcinek, D. J., O’Rourke, J. F., Wang, C., Stout, J. C., Rowe, K., Kloos, A. D., Kegelmeyer, D. A., Kostyk, S. K., Chua, P., Desmond, P., Christensen, S., Steward, C., Judd, F., Lloyd, J., Tress, B., Pugliese, M., Phan, P., Sanchez-Ramos, J., Oster, E., Bausch, J., Shinaman, A., Kayson, E., Oakes, D., Oelke, L., Butterfield, L., Cimino, C., McCall, M., Ling, L., Stell, B., Annis, J., Cha, J., Como, P., PREDICT-HD Investigators of the Huntington Study Group, The Huntington Study Group, FuRST-pHD and PREDICT-HD Investigators and Coordinators of the Huntington Study Group, Huntington Study Group TREND-HD Investigators, PREDICT-HD Investigators of the Huntington Study Group, Huntington Study Group PHAROS Investigators, and Huntington Study Group COHORT Investigators

Published
2009
Full Text
View/download PDF

34. Lithium treatment in post-psychotic depression.

Author

Van Kammen, Daniel P., Alexander, Paul E., Bunney Jr., William E., van Kammen, D P, Alexander, P E, and Bunney, W E Jr

Subjects
LITHIUM, PEOPLE with schizophrenia, DISEASES, MENTAL depression, SCHIZOPHRENIA, PEOPLE with mental illness, THERAPEUTIC use of lithium, CLINICAL trials, COMPARATIVE studies, RESEARCH methodology, MEDICAL cooperation, RESEARCH, TIME, EVALUATION research, BLIND experiment
Abstract

Six of eleven drug-free schizophrenic patients who were depressed following remission of their illness showed a significant decrease in their depressive symptomatology during a double-blind, placebo substitution lithium trial. Traditional indicators of prognosis did not predict lithium response in this small sample; the schizophrenic patients tolerated the lithium well. Lithium should be studied further in a larger patient sample as an adjunct in the treatment of post-psychotic depression, which frequently is treatment resistant. [ABSTRACT FROM AUTHOR]

Published
1980
Full Text
View/download PDF

35. Serum calcium and magnesium in schizophrenia: relationship to clinical phenomena and neuroleptic treatment.

Author

Alexander, Paul E., Van Kammen, Daniel P., Bunney Jr., William E., Alexander, P E, Van Kammen, D P, and Bunney, W E Jr

Subjects
SERUM, CALCIUM, MAGNESIUM, ANTIPSYCHOTIC agents, PEOPLE with schizophrenia, PEOPLE with mental illness
Abstract

Serum calcium and magnesium were studied in drug-free and neuroleptic-treated schizophrenic patients. Calcium and magnesium were not significantly different in 31 unmedicated schizophrenic patients compared with normal controls. Serum calcium was altered, however, in two subgroups: (1) Patients who remitted after neuroleptic withdrawal were significantly lower in calcium than those who did not remit; (2) catatonic schizophrenic patients appeared to have an increased calcium at the onset of catatonic stupor. Patients treated with pimozide were found to have a significant decreased in both calcium and magnesium compared with their drug-free values. These same patients showed a similar decrease in both electrolytes during treatment with fluphenazine, a structurally different neuroleptic drug. [ABSTRACT FROM AUTHOR]

Published
1978
Full Text
View/download PDF

36. Immunoglobulins and viral antibodies in psychiatric patients.

Author

Toorey, E F, Peterson, M R, Brannon, W L, Carpenter, W T, Post, R M, and Van Kammen, D P

Subjects
IMMUNOGLOBULIN analysis, IMMUNOGLOBULINS, PARAMYXOVIRUSES, PSYCHOSES, VIRAL antibodies
Abstract

The serum and CSF of 66 patients with functional psychoses were tested for immunoglobulins and antibodies to measles, HSV-I, CMV, and rubella viruses. Ten surgical and 80 neurological patients were controls. There were no significant findings in the serum, consistent with most previous studied. In the CSF 6 of 17 multiple admission schizophrenic patients had definite elevations of IgG or measles antibody and differed significantly from the surgical controls. Immunologically this group resembled the seriously ill neurological patients. No previous study has been made of immunoglobulins or viral antibodies in the CSF of psychiatric patients. It is concluded that further work is warranted in a search for biological subgroups of schizophrenia. [ABSTRACT FROM AUTHOR]

Published
1978
Full Text
View/download PDF

48. F09 Progression of motor symptoms prior to diagnosis in HD-gene carriers.

Author

Sills, T, Geraci, J, Vaccarino, A, Anderson, K, Borowsky, B, Giuliano, J, Guttman, M, Ho, A K, Paulsen, J, van Kammen, D P, and Evans, K

Abstract

Background Identifying sensitive, specific, and reliable indicators of disease progression in Huntington's disease (HD) is key to selecting the appropriate population for clinical trials that assess novel treatments that may slow or delay the onset of HD's debilitating symptoms. The PREDICT-HD study is an NIH and CHDI-funded study that began in 2001, with the goal of documenting the neurobiological and neurobehavioral changes that occur in HD-gene carriers in the period leading up to the diagnosis of HD. The PREDICT-HD study provides a rich source of data that can be mined to identify HD-gene carriers who show rapid progression in the early stages of the disease, prior to diagnosis based on their motor symptoms. Aims To identify a population of PREDICT-HD participants who show rapid progression in motor symptoms over the course of the first four years of the PREDICT-HD study, and to determine if there are specific measures that classify participants a priori. Methods The change in the Unified Huntington's Disease Rating Scale (UHDRS) Total Motor score between Baseline and Year 4 was calculated for all PREDICT-HD participants who had completed four annual visits. A model was generated to distinguish rapid progressors from gene-carriers not showing progression utilizing the baseline motor, cognitive, and imaging data from PREDICT-HD participants. Results Examination of the inter-quartile ranges of change-from-baseline total motor scores showed that PREDICT-HD participants in the top (fourth) quartile had a change in score of approximately 14 points; the average change in the third quartile was only 5 points. The classification model that was developed included disease burden score, striatal volume, motor and cognitive variables. The model was 82.4% accurate in identifying HD-gene carriers in PREDICT-HD who showed rapid progression in their UHDRS motor scores; the model was 91.9% accurate in identifying HD-gene carriers in PREDICT-HD who did not show a substantial increase in their motor scores. Conclusions There is a population of HD-gene carriers in the PREDICT-HD study that show a rapid progression in their motor symptoms as assessed by the UHDRS Motor Subscale. We have developed a model that is highly accurate in identifying these patients. This model needs to be further refined and validated. This model may be useful in identifying HD-gene carriers for recruitment in therapeutic clinical trials. [ABSTRACT FROM PUBLISHER]

Published
2010
Full Text
View/download PDF

49. ABNORMAL ANTIOXIDANT DEFENSE SYSTEM IN PATIENTS WITH SCHIZOPHRENIA.

Author

Yao, J. K., Reddy, R. D., and Van Kammen, D. P.

Subjects
MEDICAL research, PEOPLE with schizophrenia, NEUROCHEMISTRY, ANTIOXIDANTS
Abstract

The article presents an abstract of the medical research paper "Abnormal Antioxidant Defense System in Patients With Schizophrenia," which will be presented in the 30th meeting of the American Society for Neurochemistry which will be held in New Orleans, Louisiana. The research demonstrates that both total antioxidant status and individual antioxidants are significantly reduced in plasma of schizophrenic patients.

Published
1999

50. Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia.

Author

Yao JK, Sistilli CG, and van Kammen DP

Subjects
Chromatography, Gas methods, Cytokines blood, Cytokines cerebrospinal fluid, Enzyme-Linked Immunosorbent Assay, Fatty Acids, Unsaturated blood, Fatty Acids, Unsaturated cerebrospinal fluid, Haloperidol administration & dosage, Humans, Interleukin-10 blood, Interleukin-10 cerebrospinal fluid, Interleukin-6 blood, Interleukin-6 cerebrospinal fluid, Male, Schizophrenia blood, Schizophrenia cerebrospinal fluid, Cytokines metabolism, Erythrocyte Membrane metabolism, Fatty Acids, Unsaturated metabolism, Schizophrenia metabolism
Abstract

Findings to date provide evidence that altered membrane structure and function are present in patients with either first-episode or chronic schizophrenia, suggesting defects in phospholipid metabolism and cell signaling in schizophrenia. The purpose of this investigation is to test whether decreased membrane polyunsaturated fatty acids (PUFAs) were associated with an increased secretion of proinflammatory cytokines. Thus, we measured interleukin 6 (IL-6) and interleukin 10 (IL-10) in cerebrospinal fluid (CSF) of patients with chronic schizophrenia as well as PUFAs of red blood cell (RBC) membranes from the same individuals. A significant and inverse correlation was found between CSF IL-6 (not IL-10) and RBC membrane PUFAs levels in both haloperidol-treated and medication-free patients with schizophrenia. Specifically, such an association was found in the n-6 (18:2, 20:4, and 22:4) and, to a lesser extent, the n-3 fatty acids. Taken together, the present findings suggest that decreased membrane PUFAs may be related to an immune disturbance in schizophrenia, possibly resulting from an increased phospholipase A2 activity mediated through the proinflammatory cytokines.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results